工程化人诱导多能干细胞衍生的血管移植物为无血栓血管治疗带来希望。
Engineered hiPSC-derived vascular graft brings hope for thrombosis-free vascular therapy.
作者信息
Tamhankar Soniya, Shusta Eric V, Palecek Sean P
机构信息
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, USA; Department of Neurological Surgery, University of Wisconsin-Madison, Madison, WI, USA.
出版信息
Cell Stem Cell. 2025 Jan 2;32(1):1-3. doi: 10.1016/j.stem.2024.12.001.
Tissue-engineered vascular conduits (TEVCs) are a promising blood vessel replacement. In a recent publication in Cell Stem Cell, Park et al. developed TEVCs comprised of decellularized human umbilical arteries lined with shear-trained, human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) that resisted thrombosis and exhibited patency upon grafting into the rat inferior vena cava (IVC).
组织工程血管导管（TEVCs）是一种很有前景的血管替代物。在《细胞·干细胞》最近发表的一篇论文中，朴等人开发了由脱细胞人脐动脉组成的TEVCs，其内壁衬有经过剪切训练的、人诱导多能干细胞（hiPSC）衍生的内皮细胞（ECs），这些TEVCs能够抵抗血栓形成，并在移植到大鼠下腔静脉（IVC）后保持通畅。
Zotero 插件